FDA is aware that unapproved cannabis or cannabis-derived products are becoming used for the treatment of a number of scientific conditions which encompass, for example, AIDS wasting, epilepsy, neuropathic ache, spasticity associated with multiple sclerosis, and maximum cancers and chemotherapy-precipitated nausea. To date, FDA has now not permitted a marketing and marketing and advertising software for cannabis for the treatment of any disease or situation and hence has now not determined that cannabis is stable and effective for any unique disease or situation. The business enterprise has, but, permitted one cannabis-derived and three cannabis-related drug products (see Question #2). Bluum Lab FDA is primarily based totally on applicants and clinical investigators to conduct research. The business enterprise’s function, as laid out withinside the FD&C Act, is to test records submitted to the FDA in an software for approval to make sure that the drug product meets the statutory necessities for approval.